Loading
The whole lifecycle, verified against the filings.
Rumor → LOI → definitive → approved
Summed over 4 of 5 filed.
More equity than the headline, over 3 of 5 measured.
A definitive agreement is signed and the vote is still ahead, so the redemption right survives to it.
| SPAC | Target | Segment | Value | Announced | Vote | SPAC price | Status | ARS | Delivers | Notes |
|---|---|---|---|---|---|---|---|---|---|---|
| SPKLSpark I Acquisition Corp | ZincFive, Inc. | Battery | $600M | Jun 11, 2026 | Sep 25, 2026 · 14d | $11.58 | -15.2% | Definitive (DA signed) | 50 |
The list is grouped by lifecycle stage and the sort orders rows inside a stage: a vote that has already passed and one still ahead are not the same list. An announced deal is not a closed deal — 19 of the combinations in our record were terminated. A premium to trust is a selling point, not a buying point — and once a vote has passed there is no redemption right left to price against. Every stage, target and figure here is read from the SEC filing that stated it; where a figure is missing it is missing from our record, and the page says so rather than estimating one.
5 of 5 deals in this view carry a dated vote or a stated close period. Where the Vote column is empty, the filings we hold state neither — that is a gap in our record, not a claim that the parties have no timetable.
Sorted inside each stage.
| NHICNewHold III | newcleo | Nuclear/Energy | $2.4B | May 27, 2026 | Sep 17, 2026 · 6d | $10.62 | -0.4% | Definitive (DA signed) | 8484 | F-4/A Aug 2026; $220M PIPE |
| IBACIB Acquisition | GNQ Insilico, Inc. | AI/Tech | $500M | Mar 16, 2026 | Sep 24, 2026 · 13d | $10.92 | +1.1% | Definitive (DA signed) | 7171 | GNQ Insilico, Inc. is a TechBio company incorporated under the federal laws of Canada and headquartered in Toronto, with operations also described as California-based. Founded by Rehan Huda, who serves as the company's Founder, Chairperson, and Chief Executive Officer, GNQ Insilico is focused on transforming and de-risking drug development through the convergence of artificial intelligence, quantum computing, genomics, and systems biology. The company's mission is to revolutionize pharmaceutical R&D and healthcare delivery by enabling precision medicine at scale, leveraging digital twin technology, advanced biological modeling, and quantum-enhanced AI platforms to help pharmaceutical companies discover, develop, and optimize therapeutics more efficiently. By addressing critical inefficiencies across the healthcare value chain, GNQ aims to accelerate development timelines, reduce costs, and deliver improved patient outcomes across multiple disease areas. The company operates three proprietary AI-powered platforms: a Drug Assessment platform, which launched in the fourth quarter of 2025, and Drug Simulation and Digital Twins platforms, both expected to roll out later in 2026. These platforms are designed to serve pharmaceutical companies, investors, and healthcare providers worldwide, enabling smarter investment decisions and accelerating drug development toward truly personalized medicine. GNQ's integration of genomics, artificial intelligence, and quantum computing represents a differentiated approach to addressing the significant challenges facing drug discovery and development, positioning the company to capture meaningful market share in the precision medicine space. GNQ Insilico is going public through a definitive business combination agreement with IB Acquisition Corp. (Nasdaq: IBAC), a Nevada-based special purpose acquisition company, in a transaction structured as a statutory plan of arrangement under the Canada Business Corporations Act. The deal values GNQ at approximately US$500 million (about C$688 million), with additional consideration possible through revenue and share-price earnout provisions. The transaction is expected to provide approximately US$15 million in proceeds to GNQ, comprising a PIPE of up to US$10 million, cash held in IBAC's trust account, and up to US$2 million in bridge financing through convertible notes and warrants. The merger is expected to close in the third quarter of 2026, subject to customary closing conditions including shareholder approvals and Ontario Superior Court approval. The SPAC route provides GNQ with the resources and public market visibility needed to expand its commercial partnerships and scale its solutions globally. Following the close, GNQ's current executive team will continue to lead the combined company, with a five-member board of directors consisting of four GNQ designees and one independent IBAC sponsor designee. IBAC's CEO and Chairman Al Lopez emphasized that GNQ's differentiated approach to drug discovery and development made it an compelling partner at the forefront of innovation, expressing confidence in the talented GNQ team's ability to execute on its vision of making precision medicine accessible and economically viable for patients worldwide. Legal counsel for the transaction includes Cassels Brock & Blackwell LLP and Barnes & Thornburg LLP for GNQ, and Dentons Canada LLP and ArentFox Schiff LLP for IBAC, with I-Bankers Securities acting as financial and capital markets advisor. |
| WINVWinVest | Embed Financial | Fintech | $425M | Dec 2, 2025 | Sep 15, 2026 · 4d | — | Definitive (DA signed) | — | accreted trust |
| WELIntegrated Wellness Acquisition Corp | Btab Ecommerce Group, Inc. | Other | — | May 30, 2024 | Sep 15, 2026 · 4d | — | Definitive (DA signed) | — |